Stem Cell Therapy for Pets – WebMD

Theres controversy surrounding the use of stem cells, particularly in humans. But stem cell therapy is being used to treat beloved pets. Here’s how it works in animals.

What are stem cells?

Top 10 Reasons to Spay or Neuter Your Pet

Whether youve recently adopted a pet or youre considering it, one of the most important health decisions youll make is to spay or neuter your cat or dog. Spaying-removing the ovaries and uterus of a female pet-is a veterinary procedure that requires minimal hospitalization and offers lifelong health benefits. Neutering-removing the testicles of your male dog or cat-will vastly improve your pets behavior and keep him close to home. Many states and counties have established low-cost…

Read the Top 10 Reasons to Spay or Neuter Your Pet article > >

In all animals, stem cells are like blank slates. They start out without any clear identity, but can divide and grow into many different types of cells, like muscle or blood cells.

What is stem cell therapy?

Stem cells are being used to treat illness and heal injuries in pets. They are injected into the body to repair muscles, joints, and ligaments that have been damaged by arthritis or injury. Some cancers are treated with stem cells taken from the pet’s own bone marrow. And research is underway to test stem cells for diabetes treatment, and to treat animals that have lost control of their bladders.

Does stem cell therapy for pets work the same as in humans?

Yes. The basic idea is the same, but because there are fewer regulations for treating animals, stem cell therapy is used more often in pets than in humans.

Follow this link:
Stem Cell Therapy for Pets – WebMD

Stress Could Activate "Crosstalking" Cell Signals That Turn Bodys Natural Wound Healing Process Against It

Durham, NC (PRWEB) April 23, 2014

Stress could activate “crosstalking” cell signals that decrease the bodys natural healing process after a wound occurs, according to a new study released today in STEM CELLS Translational Medicine. The finding helps explain how stress impairs healing and, conversely, could lead to a way to overcome chronic wounds resulting from serious burns and other skin injuries.

Chronic wounds are a major global health problem, with annual costs in the United States alone of more than $23 billion, said Roslyn Isseroff, M.D., of the University of California Davis and the Northern California Health Care Systems Department of Veterans Affairs. She was a lead investigator in the study along with Mohan R. Dasu, Ph.D.

The precise process that prevents their healing is unclear except for two constants: a prolonged inflammatory response and the bacterial colonization of the wound bed. These two interrelated factors are thought to contribute to the wounds chronic state.

Previous studies had demonstrated an increase in epinephrine (adrenaline), as occurs during stress, produces an increase in the activity of TLR2 (Toll-like receptor 2), a protein that appears to stimulate the early inflammatory process needed to set the steps of healing in motion. Together they alter the ability of stem cells and keratinocytes, the barrier-forming cells that make up 90 percent of skin, to repair wound damage by slowing down the stem cells migration to the area and by promoting inflammation.

To compound the potential for damage, bacteria in the wound can activate the TLR2 system, and crosstalk to the epinephrine signaling system, creating a cycle of escalating damaging signals.

The Isseroff and Dasu team, which included colleagues at UC-Daviss Institute for Regenerative Cures and California State University, decided to look at how increased epinephrine and TLR2 stimulation affected stem cells taken from bone marrow and keratinocytes by analyzing the “crosstalk” between their signaling pathways. The researchers tested their theory in cultured cells and in mice. In both instances they found that the crosstalk led to impaired healing, with elevated levels of TLR2 as well as MyD88 and IL-6, both of which regulate the activation of numerous pro-inflammatory genes, in the wounds.

Thus, our data describe a recipe for decreasing cell migration and exacerbating inflammation via novel crosstalk between the adrenergic and Toll-like receptor pathways in wounds, Dr. Dasu said.

“These findings have implications for understanding the mechanisms controlling the differing susceptibility to infections and immune/inflammatory-related conditions in wounds,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

The full article, Crosstalk Between Adrenergic and Toll-Like Receptors in Human Mesenchymal Stem Cells and Keratinocytes: A Recipe for Impaired Wound Healing, can be accessed at http://www.stemcellstm.com.

View post:
Stress Could Activate "Crosstalking" Cell Signals That Turn Bodys Natural Wound Healing Process Against It

Stem Cells and Multiple Sclerosis – Video



Stem Cells and Multiple Sclerosis
Dr Colin Andrews speaks about the optimistic results of treating MS (multiple sclerosis) with stem cell therapy and the ethical limitations within Australia.

By: Norwood Day Surgery

Go here to see the original:
Stem Cells and Multiple Sclerosis – Video

Autologous stem cell therapy improves motor function in chronic stroke victims

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Apr. 23, 2014) People who have had a stroke, often suffer motor deficits with little potential to restore neurological function. However, a study conducted in Taiwan, that will be published in a future issue of Cell Transplantation, but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen, has found that when one group of stroke victims had their own peripheral blood stem cells (PBSCs) injected directly into the brain and a similar group did not, those who received the PBSCs experienced some “improvement in stroke scales and functional outcome.” Those in the PBSC-injected group also received injections of the growth factor granulocyte-colony stimulating factor (G-CSF), known to be potentially neuroprotective.

“In this phase 2 study, we provide the first evidence that intracerebral injection of autologous (self-donated) PBSCs can improve motor function in those who have suffered a stroke and have motor deficits as a result,” said study corresponding Dr. Woei-Cheng Shyu of the Center for Neuropsychiatry, Graduate Institute of Immunology and Translational Medicine Research Center, China Medical University in Taiwan. “Our study demonstrated that this therapeutic strategy was feasible and safe in stroke patients who suffered a prior stroke, but within five years from the onset of symptoms.”

According to the authors, there has been little advance made in restoring neurological function following ischemic stroke. However, since neuronal death is the primary mechanism that limits functional recovery, stem cell therapy is emerging as a potentially effective regenerative approach. Once more PBSCs are being increasingly used as a self-donated source for cell therapies for regenerating skeletal muscle, heart and neurons. The PBSCs may need to be “amplified” with G-CSF, speculated the researchers.

All of the patients in the trial had suffered a stroke in the past, as long as five years prior to this study. At the end of a 12 month follow-up, the group of 15 patients with neurological deficits who received injections of PBSCs experienced neurological and functional improvement based on a number of clinical outcomes measures. The control group of 15 patients with neurological deficits that did not receive the PBSC injections did not experience the same beneficial outcomes.

The researchers reported that nine of the 15 patients undergoing PBSC transplantation experienced “positive motor evoked potentials” (MEPs) after transcranial magnetic stimulation, but why MEPs appeared in some of the transplanted group, but not all, was unclear.

“Despite this success, it should be noted that this was a preliminary study and, due to the small number of patients, are tentative,” concluded the researchers. “In the future we plan to conduct a multi-center, large-scale, double blind, placebo-controlled randomized studies to better evaluate the effect of PBSC implantation in patients suffering from the effects of past stroke.”

“This phase II study offers pilot clinical evidence supporting the use of autologous stem cell-based treatment for stroke” said Dr. Cesar V. Borlongan, Prof. of Neurosurgery and Director of the Center of Excellence for Aging & Brain Repair at the University of South Florida. “Clarification of the impact of G-CSF on the cells and whether other factors are necessary to maximize the benefit of cell transplantation, as well as further studies with a larger number of patients are necessary to determine equivocal safety and efficacy of this treatment”.

Read more from the original source:
Autologous stem cell therapy improves motor function in chronic stroke victims

Day +25 post-stem-cell treatment: Easter morning – Video



Day +25 post-stem-cell treatment: Easter morning
Twenty-five days after his stem cell transplant to try to stop acute lymphoblastic leukaemia from relapsing again, George, discovers for the first time in hi…

By: giorgissimouk

The rest is here:
Day +25 post-stem-cell treatment: Easter morning – Video

Stem Cell Treatment For MS Working Wonders – Video



Stem Cell Treatment For MS Working Wonders
We are in Panama City Panama for treatment of my wife's Secondary Progressive Multiple Sclerosis. She has been through the first round of treatment with litt…

By: Stem Cell Patient

Read the original here:
Stem Cell Treatment For MS Working Wonders – Video

Stem Cell Therapy Market Worth $330 Million in 2020

DALLAS, April 23, 2014 /PRNewswire/ — According to the new research report "Stem Cell Therapy Marketby Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound …

View post:
Stem Cell Therapy Market Worth $330 Million in 2020

Miami Stem Cell Treatment Center Visits the Forum at Deer Creek: Senior Living Center

Deerfield Beach, Florida (PRWEB) April 23, 2014

The Miami Stem Cell Treatment Center, PC, located in Miami, Ft. Lauderdale, and Boca Raton, Florida, announces their invite to speak at the Forum at Deer Creek in Deerfield, Florida on the use of stem cells for various degenerative and inflammatory conditions. This will be provided by Dr. Nia Smyrniotis, Medical Director.

This seminar will be held on April 28 at 2:30 pm at the Forum at Deer Creek, 3001 Deer Creek Country Club Blvd., Deerfield Beach, FL 33442.

At the Miami Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body’s natural healing cells – they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Miami Stem Cell Treatment Center only uses autologous stem cells from a person’s own fat no embryonic stem cells are used. Our current areas of study include: heart failure, emphysema, COPD, asthma, Parkinsons disease, stroke, multiple sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Miami Stem Cell Treatment Center, they may contact Dr. Nia Smyrniotis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About Miami Stem Cell Treatment Center:

The Miami Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protections (OHRP) and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Info(at)MiamiStemCellsUSA(dot)com or visit our website: http://www.MiamiStemCellsUSA.com.

See the original post here:
Miami Stem Cell Treatment Center Visits the Forum at Deer Creek: Senior Living Center

Irvine Stem Cell Treatment Center: Upcoming Lecture at Thousand Oaks Library

Thousand Oaks, CA (PRWEB) April 23, 2014

The Irvine Stem Cell Treatment Center, PC, located in Irvine, California, announces a free public seminar on the use of stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief.

The seminar will be held on Tuesday, April 29th at 4:00 p.m. and 7:00 p.m. at the Thousand Oaks Library, 1401 E. Janss Road, Thousand Oaks, CA.

At the Irvine Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF)). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body’s natural healing cells – they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Irvine Stem Cell Treatment Center only uses autologous stem cells from a person’s own fat no embryonic stem cells are used. Our current areas of study include: Heart Failure, Emphysema, COPD, Asthma, Parkinsons Disease, Stroke, Multiple Sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Irvine Stem Cell Treatment Center, they may contact Dr. Gionis directly at (949) 679-3889, or see a complete list of the Centers study areas at: http://www.StemCellsUSA.net.

About Irvine Stem Cell Treatment Center: The Irvine Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Irvine Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Research Protections; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Info(at)StemCellsUSA(dot)net or visit our website: http://www.StemCellsUSA.net.

Original post:
Irvine Stem Cell Treatment Center: Upcoming Lecture at Thousand Oaks Library

Prosecutors say Stamina treatment hurt, not helped, patients

Charges of criminal association may be filed in medical case

(ANSA) – Turin, April 23 – Not only was a discredited stem-cell treatment useless, investigations found that it actually hurt a number of patients, prosecutors said Wednesday as they concluded a probe of 20 suspects involved in the Stamina treatment. That includes Davide Vannoni, founder of the Stamina Foundation, who may face indictment in the case now that prosecutors have finished a lengthy probe. Charges could include criminal association to commit aggravated fraud and administration of dangerous drugs, according to prosecutors whose probe examined the treatment of slightly more than 100 patients and found “adverse reactions” in some cases. Another 37 donors of stem cells used in the controversial treatment, rejected by the health ministry, were examined during the investigation. According to prosecutors, Vannoni and other suspects “falsely pretended” to patients and their families that there was “high chance” of recovery from serious illness if they agreed to the Stamina treatment. Vannoni, a former psychology lecturer who was indicted earlier this year for alleged attempted fraud against the Piedmont Region, had also tried to discredit health officials and the national health system while raising social tension, according to prosecutors. Earlier this month, hospitals in Italy that used the discredited stem-cell treatment announced they had suspended the program. That followed announcements last fall by Italy’s health ministry that the Stamina Foundation – the nonprofit foundation that developed the treatment – would not be allowed to test it on humans. The foundation was also stripped of its non-profit status after a study found its treatment was “ignorant of stem-cell biology”. Health Minister Beatrice Lorenzin said she was “not surprised” by the outcome of the investigation. “It is a story that had Italians holding their breath with many concerns and anxieties,” she said. “It is important that (the findings) come out clearly, because there are victims, the thousands of people who believed they could have a cure,” she said. The Stamina treatment involves extracting bone-marrow stem cells from a patient, turning them into neurons by exposing them to retinoic acid for two hours, and injecting them back into the patient. Supporters of the therapy thought it could be a cure for fatal degenerative nerve diseases such as spinal muscular atrophy, while detractors said it was devoid of scientific merit. A panel of experts appointed by Italy’s health ministry said in January it found the therapy seriously lacking in both premise and practice. Their report cited “serious imperfections and omissions in the Stamina protocol, including conceptual errors and an apparent ignorance of stem-cell biology”. The Stamina Foundation had asked for 500,000 euros of funding to develop a stem-cell laboratory, a request that earlier prosecutors had argued was fraudulent because the efficacy of the treatment has been “completely disproved”.

Read more:
Prosecutors say Stamina treatment hurt, not helped, patients